Canary Speech Raises $13M in Series A Funding for AI-Powered Voice Biomarker Technology
Canary Speech is at the forefront of integrating voice biomarker technology into healthcare, providing rapid, non-invasive diagnostics for conditions like anxiety, depression, and dementia.
Company Name: Canary Speech
Location: Provo, UT, USA
Sector: Health Tech, Artificial Intelligence
Funding Details: Raised $13m in Series A funding. The round was led by Cortes Capital (Love’s Private Equity), with participation from Sorenson Communications, SMK, and Hackensack Meridian Health.
Purpose of Investment: To expand the team to support growth driven by advancements in artificial intelligence and increasing demand from the healthcare industry for advanced diagnostic tools.
Leadership: Led by CEO Henry O’Connell.
Product: Canary Speech specializes in AI-powered voice biomarker technology for the healthcare sector. The company’s innovative vocal analysis platform screens for mental health and neurological disorders by capturing and analyzing speech data in real-time. This allows for the early detection of behavioral and cognitive changes before they become apparent through clinical screenings or symptoms.
About Company: Canary Speech is at the forefront of integrating voice biomarker technology into healthcare, providing rapid, non-invasive diagnostics for conditions like anxiety, depression, and dementia. The company’s API-first approach enables its technology to be integrated across various applications, including contact centers, ambient clinical listening, remote patient monitoring, and wellness checks.